Navigation Links
DrugRisk Center Adds Latest on First of 3,000 Actos Bladder Cancer Trials
Date:3/28/2013

New York, NY (PRWEB) March 28, 2013

The prescription drug resource center DrugRisk.com is announcing new information to the site for those who have taken the medication Actos for diabetes. With drug maker Takeda facing claims from patients alleging bladder cancer, the first trial is underway in California.

The goal of DrugRisk is to improve the safety of patients taking popular prescription drugs by providing the most up-to-date warnings, recalls, studies and legal news. Visitors can determine if others have experienced similar side effects and decide if they need legal advice.

The resource center contains warnings from experts such as the FDA and European Medicines Agency*, who have warned that long-term use of Actos may be associated with an increased bladder cancer risk. The drug has also been banned in France and Germany**.

Although Actos remains on the market in the United States, DrugRisk has learned that as many as 3,000 patients have filed an Actos lawsuit against drug maker Takeda Pharmaceuticals alleging they developed bladder cancer***. Over 1,200 of these have been consolidated in a special multi-district federal court in Louisiana, while others are pending in California.

The resource center has added information from the first of these Actos lawsuit trials, which began this month in California for a retired man dying of bladder cancer***. A former pharmacologist for Takeda testified that, as news of bladder cancer risks spread, executives were more concerned with maintaining sales than the safety of patients***.

Anyone affected by bladder cancer after taking Actos is urged to contact DrugRisk or speak with a lawyer about their legal rights as soon as possible. Lawyers are still helping those affected file claims.

Due to the specialized nature of drug injury litigation, however, DrugRisk only recommends lawyers and law firms who have already handled Actos lawsuits.

To learn more about the studies linking Actos to bladder cancer, as well as Actos side effects and legal news, or to speak with a lawyer, visit http://www.DrugRisk.com today.

*fda.gov/ForConsumers/ConsumerUpdates/ucm263431.htm#Actos; ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/public_health_alerts/2011/07/hu an_pha_detail_000033.jsp&mid=WC0b01ac058001d126
**cbsnews.com/8301-504763_162-20070492-10391704.html
***bloomberg.com/news/2013-03-05/takeda-put-actos-sales-ahead-of-user-safety-witness-says.html; Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court (Los Angeles).

Read the full story at http://www.prweb.com/releases/actos-lawsuits/bladder-cancer-lawsuit/prweb10579370.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisk Center Announces Court Postponement of NuvaRing Lawsuits
2. DrugRisk Announces Alternative to Mirena IUD May Be Available Soon
3. DrugRisk Announces Updated Information on Mirena Lawsuits
4. DrugRisk Adds Latest Health Warnings and Lawsuit Updates for Yaz
5. DrugRisk Announces New Pradaxa Health Warning From Australia
6. DrugRisk Update: NuvaRing Lawsuit Trials to Begin This Year
7. DrugRisk Update: Court Allows Charges of Prior Fraud Into Pradaxa Lawsuit
8. DrugRisk Pradaxa Lawsuit Update: Court Denys Boehringer’s Protective Order Request
9. DrugRisk Pradaxa Update: Litigation Grows As New Study Adds to Risks
10. DrugRisk Update: Bayer Discloses $500 Million Remaining for Yaz Lawsuits
11. DrugRisk Update: Evidence Submitted in Actos Lawsuit Suggests Drug Maker Knew of Cancer Risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
(Date:10/12/2017)... Malvern, PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best ... New York City on October 11, 2017. , The annual award competition recognizes editorial ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... the nation's first interactive health literacy software tool, and the Cancer Patient Education ... of cancer patient education, today announce a new strategic alliance. , As ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical (AVACEN) ... is now successfully helping those with the widespread pain ... Fibromyalgia diagnosed Amanda in Essex, England ... washing my hair, experiencing no sleep at all, tremendous ... spasm… I cannot recommend [the AVACEN 100] enough, how ...
(Date:9/19/2017)...   ZirMed Inc ., a recognized leader in cloud-based ... has been ranked #1 by its users for the seventh ... User Survey. ZirMed was recognized as the top-ranked end-to-end revenue ... centers over 200 beds and holds one of the longest ... history. ...
Breaking Medicine Technology: